Estrogen therapy may cause an exacerbation of asthma, diabetes mellitus, epilepsy, migraine, porphyria, systemic lupus erythematosus, and hepatic hemangiomas and should be used with caution in women with these conditions. Laboratory Tests

Climea Forte helps in relieving the symptoms of menopause, including hot flushes, sweating, anxiety, irritability (hops extract). Supports weight control and helps maintain digestive comfort (flax). Supports the maintenance of healthy bones (calcium and vitamin D), contributes to the reduction of tiredness and fatigue (vitamin B6, folates). Also helps to protect cells against oxidative stress (vitamin E) and supports the proper functioning of the nervous system (vitamin B6). handling complaints – legitimate interest of the Controller – Article 6(1)(f) of the GDPR. The basis for personal data processing will be Article 6(1)(b) of the GDPR, where necessary to perform a contract to which you are a party or to take steps at your request prior to entering into a contract.replying to a question/request concerning products, cooperation or business of Aflofarm – the legal basis for processing is your consent or a legitimate interest of the Controller – Article 6(1)(a) and (f) of the GDPR; Climea Forte, a special supplement that affects the well-being and alleviate the discomfort of women, associated with menopause. The composition of the preparation is a double dose of soy isoflavones, which are classified as phytoestrogens - or plant counterparts of female hormones. Soy isoflavones are safe and have a mild effect on the endocrine women - without causing side effects. Due to the increased content of calcium and vitamin D3 Climea forte, also it allows you to maintain the proper structure and bone density. Enriched with the preparation that improves the appearance of the skin, and also relieves symptoms of fatigue and irritability associated with the menopause. Estrogens may be poorly metabolized in women with impaired liver function. For women with a history of cholestatic jaundice associated with past estrogen use or with pregnancy, caution should be exercised, and in the case of recurrence, medication should be discontinued. Hypothyroidism https://www.termedia.pl/Wplyw-zmian-hormonalnych-zachodzacych-w-organizmie-kobiety-na-stan-skory,56,12608,0,0.html

All women should receive yearly breast examinations by a healthcare provider and perform monthly breast self-examinations. In addition, mammography examinations should be scheduled based on patient age, risk factors, and prior mammogram results. Ovarian CancerThe WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. After an average follow-up of 5.6 years, the relative risk for ovarian cancer for CE plus MPA versus placebo was 1.58 (95 percent CI, 0.77-3.24). The absolute risk for CE plus MPA versus placebo was 4 versus 3 cases per 10,000 women-years. 7 A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The primary analysis, using case-control comparisons, included 12,110 cancer cases from the 17 prospective studies. The relative risks associated with current use of hormonal therapy was 1.41 (95% confidence interval [CI] 1.32 to 1.50); there was no difference in the risk estimates by duration of the exposure (less than 5 years [median of 3 years]vs. greater than 5 years [median of 10 years] of use before the cancer diagnosis). The relative risk associated with combined current and recent use (discontinued use within 5 years before cancer diagnosis) was 1.37 (95% CI 1.27 to 1.48), and the elevated risk was significant for both estrogen-alone and estrogen plus progestin products. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown. Probable Dementia The data described below reflect pooled data from 5 clinical trials of Climara Forte. A total of 614 women were exposed to Climara Forte for 3 months (193 women at 0.025 mg per day, 201 women at 0.05 mg per day, 194 women at 0.1 mg per day) in randomized, double-blind trials of clinical efficacy versus placebo and versus active comparator. All women were postmenopausal, had a serum estradiol level of less than 20 pg/mL, and a minimum of five moderate to severe hot flushes per week or a minimum of 15 hot flushes per week of any severity at baseline. Included in this table are an additional 25 postmenopausal hysterectomized women exposed to Climara Forte 0.025 mg per day for 6 to 24 months (N=16 at 24 months) in a randomized, double-blind, placebo-controlled study of Climara Forte for the prevention of osteoporosis. There are, however, possible risks that may be associated with the use of progestins with estrogens compared to estrogen-alone regimens. These include an increased risk of breast cancer. Elevated Blood Pressure Figure 1: Mean Serum 17β -Estradiol Concentrations versus Time Profile following Application of a 6.5 cm² Transdermal System and Application of a 12.5 cm² Climara Forte Transdermal System

Table 2 provides a summary of estradiol pharmacokinetic parameters determined during evaluation of the Climara Forte transdermal system. After an average follow-up of 5.2 years, 28 women in the estrogen-alone group and 19 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE-alone versus placebo was 1.49 (95 percent CI, 0.83-2.66). The absolute risk of probable dementia for CE-alone versus placebo was 37 versus 25 cases per 10,000 women-years 8. Climara Forte has also been shown to exert favorable effects on bone density by inhibiting bone resorption. Estrogen appears to inhibit bone resorption and may have beneficial effects on the plasma lipid profile. Estrogens cause an increase in hepatic synthesis of various proteins, which include sex hormone binding globulin (SHBG), and thyroid-binding globulin (TBG). Estrogens are known to suppress the formation of follicle-stimulating hormone (FSH) in the anterior pituitary gland. The most important randomized clinical trial providing information about breast cancer in estrogen plus progestin users is the WHI substudy of daily CE (0.625 mg) plus MPA (2.5 mg). After a mean follow-up of 5.6 years, the estrogen plus progestin substudy reported an increased risk of invasive breast cancer in women who took daily CE plus MPA. Dose proportionality was demonstrated for the Climara Forte 6.5 cm² transdermal system as compared to the Climara Forte 12.5 cm² transdermal system in a 2-week crossover study with a 1-week washout period between the two-transdermal systems in 24 postmenopausal women.In the WHIMS estrogen-alone ancillary study of WHI, a population of 2,947 hysterectomized women 65 to 79 years of age was randomized to daily CE (0.625 mg)-alone or placebo. Therapy with estrogens should be administered cautiously in patients with preexisting hypertension. Curb JD, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Arch Int Med. 2006;166:772-780. Mamy podaną konkretną ilość tych fitohormonów – czyli izoflawonów z nasion soi – na plus – to najważniejszy składnik Climei Forte. Increased TBG levels leading to increased circulating total thyroid hormone, as measured by protein-bound iodine (PBI), T4 levels (by column or by radioimmunoassay) or T3 levels by radioimmunoassay. T3 resin uptake is decreased, reflecting the elevated TBG. Free T4 and free T3 concentrations are unaltered. Women on thyroid replacement therapy may require higher doses of thyroid hormone.